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Hyperemesis Gravidarum is associated with
substantial economic burden in addition to
severe physical and psychological suffering
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Abstract
Hyperemesis gravidarum (HG) affects 1 % of all pregnant women and in western societies it is the most common
cause for hospital admission during first trimester. The economic burden of the disease has barely been studied. To
estimate the Israeli national burden of HG, Konikoff and co-workers obtained data retrospectively on hospital costs
as well as loss of workdays from 184 women hospitalized due to HG from December 2010 until December 2013.
Their findings emphasise the need for better treatment to reduce the burden of this disease both for the individual
as well as the society.
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Background
The most extreme form of nausea and vomiting in preg-
nancy (NVP); Hyperemesis Gravidarum (HG), severely
affects women’s wellbeing and inhibits performance of
normal daily living, including work, whether paid or un-
paid as family/house caretakers [1]. Women with HG
often require hospitalization, explaining why this condi-
tion is the most common reason for hospitalization dur-
ing the first trimester of pregnancy [2, 3]. The etiology
of HG remains unknown, although some risk factors
have been identified. HG is inherited from mother to
daughters and are twice as common in monozygotic as
dizygotic twins, suggesting a genetic component [4–6].
Helicobacter pylori infection is the most prevalent envir-
onmental factor [7, 8]. Physicians have also been afraid
of treating HG patients, given the fact that Thalidomide
was given women suffering from NVP in the 1950s
causing limb deformities in thousands of babies [9].
Studies exploring the economic burden of HG are
sparse. Thus the study from Konikoff and co-workers
[10] is clearly welcomed.
In the Konikoff study, data obtained from a 3-years
cohort comprising 184 women hospitalized due to HG
at the Galilee Medical Center and the hospital’s birth
registry were used to estimate the incidence of HG;
1.2 %. Based on the number of days in hospital (mean
2.2) and post-hospital rest days (mean 4.6), the total
annual cost in the Western Galilee was estimated to be
approximate 453 thousand NIS (110 thousand USD).
When taking into account the nearly 171,000 yearly de-
liveries in Israel per year, the total national economic
burden due to HG was estimated to be 20 million NIS
(approximately 5.2 million USD).
This is a large sample study, covering hospitalization
due to HG over three years and the first study to eluci-
date HG in this region. The focus on the economic im-
pact of HG is important.
Context
The estimated incidence of 1.2 % in this Northern Israeli
hospital cohort [10] is well within rates reported from
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other industrialized countries; Norway 1.1 % [11], USA
1.2 % [12], England 1.5 % [13] and Japan 3.6 % [14].
In Norway between 0.8 to 3.2 % women (or pregnan-
cies) develop HG, where the prevalence is found to dif-
fer according to maternal country of birth. Primiparous
women born in India and Sub-Saharan Africa were
three times more likely to develop HG compared to
those born in Norway [15]. These differences could not
be explained by differences in socio economic factors,
such as maternal length of education. Differences in
help-seeking behaviour or differences in availability of
health service could, however, partly explain these find-
ings; although in Norway health services are based on
equality and are free of charge. Moreover, both genetic
and lifestyle factors are believed to contribute to the
development of HG, but the etiology remains mostly
unknown [16]. While the study from Konikoff [10] did
not reveal any significant difference in incidence of HG
between women of Arabic and Jewish ethnicity, this
can either be seen as weakening the genetic risk
hypothesis or suggest that the women of Arabic and
Jewish origin studied are genetically closely related.
Alternatively, since HG is inherited from mothers to
daughters, the results may reflect common environ-
mental factors transferred along the maternal line; i.e.
lifestyle factors such as diet, helicobacter pylori etc. An
earlier study from southern Israel [17] estimated an
overall incidence of HG as 0.6 %, but in relation to the
total birthing population Jewish women had signifi-
cantly higher risk of hospitalization compared to the
Arabic Bedouin population. We interpret this to most
likely represent cultural or environmental differences
rather than disease incidence.
The Konikoff-study has some limitations: The Israeli
Jewish population comprise several different sub
groups due to immigration from Eastern Europe,
including USSR, and North Africa; this complicates
interpretation of ethnic differences - which was a main
outcome in their study. Information on education,
known to reflect socio economic status, is valuable
when exploring differences between ethnic groups.
Not having this information is considered a limitation;
also because HG is associated with length of educa-
tion. Moreover; HG is also associated with maternal
smoking habits, which have been suggested to differ
between the two ethnic groups. Not having accurate
information of smoking habits may have influenced
the study’s findings.
HG is known to reduce women’s quality of life (QOL)
in the short term [18]. One study compared the inten-
sity of symptoms among 160 pregnant women at
11 weeks to the symptoms of nausea and vomiting
experienced by patients receiving chemotherapy [19].
The findings showed that the intensity of “normal”
nausea and vomiting at 11 weeks was comparable to
the kind of nausea patients experience in the wake of
moderately nausea-producing chemotherapy. Whether
HG has consequences for women’s long-term quality of life
has not yet been studied. Previous studies have, however,
showed that women with severe HG are less able to
welcome another pregnancy and that they are known to
consider terminating their next pregnancy due to previous
suffering [20, 21].
The specific pregnancy unique questionnaire of em-
esis (PUQE) has been validated in several settings and
languages [22, 23]. Three questions quantify nausea,
retching and vomiting and sum up as a PUQE-score
from 3 (no NVP) to 15 (≥13 defined as HG), and the
questionnaire also includes one Quality of Life (QOL)
question which is scored from 0 (poor) to 10. A
Norwegian study describes high PUQE-scores (median
13) and low QOL score (median 3) when HG patients
were admitted to hospital [23]. Following treatment
(antiemetics and fluid-/nutritional regimens) the PUQE-
score decreased and QOL score increased to the same
levels as those found in a control group of healthy preg-
nant women. Thus hospital treatment reduces the burden
of disease on an individual level.
How does this disease burden relate to economic costs?
A Canadian study [24] estimated direct (medication,
hospital/health care cost) and indirect costs (sick leave) of
139 women calling their NVP helpline. For women classi-
fied as severe NVP this amounted to $653 (Canadian
dollar) total weekly cost.
They calculated a mean 23 days lost from work per
woman. This is significantly more than the sum of hos-
pital days and post-hospital rest days noted in this
present study from Konikoff and coworkers (6 days)
[10]. Since the Konikoff study did not take into account
any sick-leave prior to the hospital stay or after the ad-
vised rest-days, we suspect that the actual cost is even
larger than the estimate from the Konikoff-study.
Piwko also performed a US estimate of direct and in-
direct cost from HG [25]. This totaled as $ 185 millions
(USD) or $7,089 per woman in 2012.
An estimate of annual hospital costs due to HG in
England in 2003/2004, based on National Health Service
reports on mean hospital stay of 3.5 days per admission,
totalled £ 36.5 million (GBP, approximately 53.3 USD)
[26]. In that same review, the authors described an al-
most three-fold rise in hospital admissions due to HG
from 1989/99 until 2005/2006, explained mainly by the
lack of early treatment of NVP in England in those years.
Thus the Israeli report from Konikoff [10] are in line
with those from Canada, England, Israel and USA in
underscoring HG as having substantial economic impli-
cations for society.
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How can the burden of HG possibly be reduced?
– Decrease incidence by initiating proper antiemetic
treatment.
In general, HG is understood as the extreme variant
of NVP [26]. Thus, treating symptoms of NVP at an
early stage may prevent development of the severe
form. No large randomized controlled study has been
performed evaluating whether early initiation of anti-
emetic treatment may reduce the incidence of HG.
However, ecologic studies indirectly indicate this, due
to the fact that when a former widely used medica-
tion approved for treatment of NVP was retracted
from the US marked in 1983, the hospitalization due
to HG steeply increased [27].
Hyperemesis in a former pregnancy is the strongest
risk factor for developing HG; primigravidas have a
1 % incidence of HG while women who suffered
from HG in a former pregnancy have 15 % recur-
rence risk (Odds Ratio 26) as opposed to women
without HG in their first pregnancy have a 0.7 % risk
of developing HG in a following pregnancy [28]. One
randomized controlled study where 60 women who
suffered from severe NVP in a former pregnancy
were allocated to either start on antiemetics immedi-
ately when their pregnancy was recognized or start
when symptoms of NVP developed. In the preemtive
group 15 % developed severe NVP (PUQE ≥ 11) while
in the symptom-based treatment group 39 % devel-
oped severe NVP [29].
We propose that antiemetic treatment could contrib-
ute to the reduction of expenditures due to HG by redu-
cing the incidence as well as severity of HG.
– Day care treatment rather than hospital admission is
feasible and less costly.
In general women with HG will be admitted to hos-
pital for rehydration and nutritional therapy.
Two randomized studies allocating women with mod-
erate/severe NVP to rehydration as inpatient or out-
patient both demonstrated significantly shorter length of
hospital stay of the day-care group but with similar satis-
faction scores [30, 31]. Using the latter study in a
Markov model for cost utility analyses, Murphy and col-
laborators found day-care treatment as significantly less
costly; €985 (EUR approximately 1,205 USD) versus
€3837 (approximately 4,692 USD) for in-patient treat-
ment [32].
– Nutritional treatment by tube feeding is less costly
than parenteral nutrition and may be continued as
out-patient
Although first line treatment of HG patients is based on
antiemetics and rehydration, these patients are at risk of
severe under-nutrition. A South-African and a Norwegian
study both document very low 24-h nutritional intake
in HG patients (median 1035 kcal and 990 kcal respect-
ively) [23, 33]. Parenteral nutrition (by venous catheters)
carries risks of serious complications such as sepsis,
thrombosis and pneumothorax and will usually need
hospitalization [34, 35]. In a 10-year hospital cohort
Stokke and collaborators [36] identified 107 patients (out
of 558 women hospitalized due to HG) who were treated
with tube feeding and documented their reversal of weight
loss. 58 of these women continued tube feeding at home
after discharge. In general, enteral nutrition (tube feeding)
is less costly than parenteral nutrition [37], but cost-
benefit analyses regarding these treatment modalities in
HG are lacking.
Directions for further research
Several factors hamper HG research:
– We need a consensus on the definition of HG and
on core outcomes in order to be able to compare
different studies.
– Larger placebo-controlled studies are needed to de-
termine efficacy and side effects of treatments. At
present there is insufficient evidence to prefer any
specific antiemetic regimen.
– Antiemetics should be evaluated specifically for
NVP/HG, with a focus on the risk of malformations
and other possible fetal effects are important. Even
though there is substantial evidence of no increased
risk from antihistamines, these are still not formally
approved as treatment of NVP or HG in several
countries.
– The role of nutritional support for HG patients
should be clarified.
– All effects of treatment should be evaluated on an
individual level (patient satisfaction), as well as in
relation to the economic burden for society.
– Long as well as short term maternal and fetal
complications due to nutritional deficiencies should
be explored.
Conclusion
Hyperemesis gravidarum is a condition with substantial
economic burden in addition to severe physical and
psychological suffering. This disease needs to be further
explored, and we suggest a major focus on modifiable
risk factors and better treatment regimen. With im-
proved therapy hopefully we can reduce the burden for
affected women as well as society.
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